Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.68 |
| ▸ | WNT3A | P56704 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | TPMT | P51580 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9364577 | 0.92 | CYP1A2 (0.96) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL1493250 | 0.90 | CYP1A2 (1.00) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL11805654 | 0.87 | CYP1A2 (0.61) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL15100716 | 0.87 | CYP1A2 (0.61) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL7867471 | 0.86 | TUBB4A (0.69) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL7373760 | 0.86 | SLC22A6 (0.83) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL6872165 | 0.85 | TSHR (0.81) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL2601961 | 0.85 | CYP1A2 (0.81) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL4818731 | 0.85 | ALDH1A1 (1.00) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL1333620 | 0.85 | CYP1A2 (0.81) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0855379-A1 | Methods for the preparation of benzophenones derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-29 | — | — | EP | claimed |
| JP-10204021-A | — | — | None | — | — | JP | disclosed |
| US-20230192908-A1 | BIOMASS-DERIVED PHOTOINITIATORS | BOWLING GREEN STATE UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021236563-A1 | BIOMASS-DERIVED PHOTOINITIATORS | BOWLING GREEN STATE UNIVERSITY (US) | 2021-11-25 | — | — | WO | disclosed |
| EP-1361210-B1 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | CELGENE CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7019030-B2 | Cyano and carboxy derivatives of substituted styrenes; inhibitors of tumor necrosis factor alpha, nuclear factor kappa B, and phosphodiesterase | CELGENE CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040019106-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1361210-A2 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | CELGENE CORPORATION (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-0918746-B1 | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20030045726-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-03-06 | — | — | US | disclosed |
| US-20010056107-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2001-12-27 | — | — | US | disclosed |
| EP-0855379-B1 | Methods for the preparation of benzophenone derivatives | HOFFMANN LA ROCHE (CH) | 2001-09-05 | — | — | EP | disclosed |
| US-6262101-B1 | ALPHA-PYRROLIDINE, IMIDAZOLE AND THIOPHENE-SUBSTITUTED STYRENE DERIVATIVES; INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA, NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE | CELGENE CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6130226-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| US-5929117-A | COMPOUNDS WHICH MEDIATE ACTION OF PHOSPHODIESTERASE AND FORMATION OF TUMOR NECROSIS FACTOR AND NUCLEAR FACTORS | CELGENE CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0918746-A1 | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5877353-A | Process for the preparation of benzophenone derivatives | HOFFMANN-LA ROCHE INC. (US) | 1999-03-02 | — | — | US | disclosed |
| JP-H10204021-A | PRODUCTION OF BENZOPHENONE DERIVATIVE | F HOFFMANN LA ROCHE AG | 1998-08-04 | — | — | JP | disclosed |
| EP-0855379-A1 | Methods for the preparation of benzophenones derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-29 | — | — | EP | disclosed |
| WO-1998006692-A1 | NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045726-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP2C19 4166/4885CYP3A4 3495/4885 |
| US-20230192908-A1 | BIOMASS-DERIVED PHOTOINITIATORS | BLVRB, CYP1B1, GLB1 | CYP1A2 39/4885CYP2C19 148/4885CYP3A4 30/4885 |
| US-20040019106-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP2C19 4166/4885CYP3A4 3495/4885 |
| US-20010056107-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP2C19 4166/4885CYP3A4 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.